DUPIXENT blocks the signaling of two key sources of Type 2 inflammation (IL-4 and IL-13). This inflammation is an important
component in the development of asthma, eczema, chronic obstructive pulmonary disease, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic spontaneous urticaria, and bullous pemphigoid.

The mechanism of dupilumab action has not been definitively established.

To learn more, explore our How DUPIXENT Works pages for your condition:

• Uncontrolled moderate-to-severe eczema (atopic dermatitis or AD) for ages 6+ months
• Add-on maintenance treatment for uncontrolled moderate-to-severe eosinophilic or oral steroid dependent asthma for
  ages 6+ years
  • DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine.
• Add-on maintenance treatment for inadequately controlled chronic obstructive pulmonary disease (COPD) with high blood eosinophils for ages 18+ years
  • DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine.
• Add-on maintenance treatment for uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) for ages 12+ years
• Allergic fungal rhinosinusitis (AFRS) for ages 6+ years
• Eosinophilic esophagitis (EoE) for ages 1+ years, who weigh at least 33 lb (15 kg)
• Prurigo nodularis (PN) for ages 18+ years
• Chronic spontaneous urticaria (CSU) with hives not controlled by H1 antihistamines for ages 12+ years
  • DUPIXENT is not used to treat any other forms of hives (urticaria).
• Bullous pemphigoid (BP) for ages 18+ years